| Dermatitis, Atopic
Opzelura vs Vtama
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Opzelura vs Vtama with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVtama has a higher rate of injection site reactions vs Opzelura based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vtama but not Opzelura, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Opzelura
Vtama
At A Glance
Topical
Twice daily
JAK inhibitor
Topical
Daily
AhR agonist
Indications
- Dermatitis, Atopic
- Vitiligo
- Psoriasis vulgaris
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic Apply a thin layer topically twice daily to affected areas of up to 20% body surface area; do not use with occlusive dressings; adults and pediatric patients 12 years and older: max one 60 gram tube per week or one 100 gram tube per 2 weeks; pediatric patients 2 to 11 years: max one 60 gram tube per 2 weeks.
Vitiligo Apply a thin layer topically twice daily to affected areas of up to 10% body surface area; max one 60 gram tube per week or one 100 gram tube per 2 weeks.
Psoriasis vulgaris, Dermatitis, Atopic Apply a thin layer to affected areas once daily; wash hands after application unless VTAMA cream is for treatment of the hands; not for oral, ophthalmic, or intravaginal use.
Contraindications
—
—
Adverse Reactions
Most common (>=1%) - Atopic Dermatitis nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, rhinorrhea, upper respiratory tract infection, COVID-19, application site reactions, pyrexia, white blood cell decreased
Most common (>=1%) - Nonsegmental Vitiligo application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, pyrexia
Most common (>=1%) - Plaque Psoriasis Folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, influenza
Most common (>=1%) - Atopic Dermatitis Upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, abdominal pain
Pharmacology
Ruxolitinib is a JAK inhibitor that inhibits JAK1 and JAK2, which mediate signaling of cytokines and growth factors important for hematopoiesis and immune function; JAK signaling involves STAT recruitment to cytokine receptors, activation, and nuclear localization leading to modulation of gene expression.
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist; the specific mechanisms by which VTAMA cream exerts its therapeutic actions in plaque psoriasis and atopic dermatitis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Opzelura
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Vtama
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Opzelura
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Vtama
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Opzelura
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Vtama
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OpzeluraView full Opzelura profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.